2
|
Morsy H, Benkirane M, Cali E, Rocca C, Zhelcheska K, Cipriani V, Galanaki E, Maroofian R, Efthymiou S, Murphy D, O'Driscoll M, Suri M, Banka S, Clayton-Smith J, Wright T, Redman M, Bassetti JA, Nizon M, Cogne B, Jamra RA, Bartolomaeus T, Heruth M, Krey I, Gburek-Augustat J, Wieczorek D, Gattermann F, Mcentagart M, Goldenberg A, Guyant-Marechal L, Garcia-Moreno H, Giunti P, Chabrol B, Bacrot S, Buissonnière R, Magry V, Gowda VK, Srinivasan VM, Melegh B, Szabó A, Sümegi K, Cossée M, Ziff M, Butterfield R, Hunt D, Bird-Lieberman G, Hanna M, Koenig M, Stankewich M, Vandrovcova J, Houlden H. Expanding SPTAN1 monoallelic variant associated disorders: From epileptic encephalopathy to pure spastic paraplegia and ataxia. Genet Med 2023; 25:76-89. [PMID: 36331550 PMCID: PMC10620943 DOI: 10.1016/j.gim.2022.09.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 09/23/2022] [Accepted: 09/25/2022] [Indexed: 11/06/2022] Open
Abstract
PURPOSE Nonerythrocytic αII-spectrin (SPTAN1) variants have been previously associated with intellectual disability and epilepsy. We conducted this study to delineate the phenotypic spectrum of SPTAN1 variants. METHODS We carried out SPTAN1 gene enrichment analysis in the rare disease component of the 100,000 Genomes Project and screened 100,000 Genomes Project, DECIPHER database, and GeneMatcher to identify individuals with SPTAN1 variants. Functional studies were performed on fibroblasts from 2 patients. RESULTS Statistically significant enrichment of rare (minor allele frequency < 1 × 10-5) probably damaging SPTAN1 variants was identified in families with hereditary ataxia (HA) or hereditary spastic paraplegia (HSP) (12/1142 cases vs 52/23,847 controls, p = 2.8 × 10-5). We identified 31 individuals carrying SPTAN1 heterozygous variants or deletions. A total of 10 patients presented with pure or complex HSP/HA. The remaining 21 patients had developmental delay and seizures. Irregular αII-spectrin aggregation was noted in fibroblasts derived from 2 patients with p.(Arg19Trp) and p.(Glu2207del) variants. CONCLUSION We found that SPTAN1 is a genetic cause of neurodevelopmental disorder, which we classified into 3 distinct subgroups. The first comprises developmental epileptic encephalopathy. The second group exhibits milder phenotypes of developmental delay with or without seizures. The final group accounts for patients with pure or complex HSP/HA.
Collapse
Affiliation(s)
- Heba Morsy
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom; Department of Human Genetics, Medical Research Institute, Alexandria University, Alexandria, Egypt.
| | - Mehdi Benkirane
- Department of Molecular Genetic, University Institute for Clinical Research, Montpellier University Hospital, PhyMedExp, CNRS UMR 9214, INSERM U1046, Montpellier, France
| | - Elisa Cali
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Clarissa Rocca
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Kristina Zhelcheska
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Valentina Cipriani
- William Harvey Research Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; UCL Institute of Ophthalmology, University College London, London, United Kingdom
| | - Evangelia Galanaki
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Reza Maroofian
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Stephanie Efthymiou
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - David Murphy
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom
| | - Mary O'Driscoll
- West Midlands Regional Clinical Genetics Service, Birmingham Health Partners, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom
| | - Mohnish Suri
- Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
| | - Siddharth Banka
- Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom
| | - Jill Clayton-Smith
- Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom
| | - Thomas Wright
- Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom
| | - Melody Redman
- Department of Clinical Genetics, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
| | | | - Mathilde Nizon
- Thorax Institute, Nantes University, CNRS, INSERM, Nantes, France
| | - Benjamin Cogne
- Thorax Institute, Nantes University, CNRS, INSERM, Nantes, France; Department of Medical Genetics, Nantes University Hospital, Nantes, France
| | - Rami Abu Jamra
- MVZ for Diagnostic and Therapy, Leipziger Land, Leipzig, Germany; Institute of Human Genetics, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany
| | - Tobias Bartolomaeus
- MVZ for Diagnostic and Therapy, Leipziger Land, Leipzig, Germany; Institute of Human Genetics, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany
| | - Marion Heruth
- MVZ for Diagnostic and Therapy, Leipziger Land, Leipzig, Germany
| | - Ilona Krey
- Institute of Human Genetics, University of Leipzig Medical Center, University of Leipzig, Leipzig, Germany
| | - Janina Gburek-Augustat
- Division of Neuropediatrics, Hospital for Children and Adolescents, University Hospital Leipzig, Leipzig, Germany
| | - Dagmar Wieczorek
- Institute of Human Genetics, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Felix Gattermann
- Institute of Human Genetics, Medical Faculty, University Hospital Düsseldorf, Düsseldorf, Germany
| | - Meriel Mcentagart
- Medical Genetics, St George's University Hospitals NHS Foundation Trust, London, United Kingdom
| | - Alice Goldenberg
- Department of Medical Genetics, Rouen University Hospital, Rouen, France
| | | | - Hector Garcia-Moreno
- Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Paola Giunti
- Department of Neurogenetics, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Ataxia Centre, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, United Kingdom
| | - Brigitte Chabrol
- Reference Center for Inherited Metabolic Diseases, Marseille University Hospital, Marseille, France
| | - Severine Bacrot
- Department of Molecular Genetics, Versailles Hospital, Versailles, France
| | | | - Virginie Magry
- Department of Molecular Genetics, Amiens-Picardie University Hospital, Amiens, France
| | - Vykuntaraju K Gowda
- Department of Pediatric Neurology, Indira Gandhi Institute of Child Health, Bangalore, India
| | | | - Béla Melegh
- Department of Medical Genetics, Clinical Centre, School of Medicine, University of Pécs, Pécs, Hungary
| | - András Szabó
- Department of Medical Genetics, Clinical Centre, School of Medicine, University of Pécs, Pécs, Hungary
| | - Katalin Sümegi
- Department of Biochemistry and Medical Chemistry, Medical School, University of Pécs, Pécs, Hungary
| | - Mireille Cossée
- Department of Molecular Genetic, University Institute for Clinical Research, Montpellier University Hospital, PhyMedExp, CNRS UMR 9214, INSERM U1046, Montpellier, France
| | - Monica Ziff
- Clinical Genetics Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
| | - Russell Butterfield
- Division of Pediatric Neurology, Department of Pediatrics, University of Utah School of Medicine, University of Utah Health, Salt Lake City, UT
| | - David Hunt
- Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, United Kigngdom
| | - Georgina Bird-Lieberman
- Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
| | - Michael Hanna
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Michel Koenig
- Department of Molecular Genetic, University Institute for Clinical Research, Montpellier University Hospital, PhyMedExp, CNRS UMR 9214, INSERM U1046, Montpellier, France
| | | | - Jana Vandrovcova
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom
| | - Henry Houlden
- Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, Queen Square, London, United Kingdom.
| |
Collapse
|